Modified-vaccinia-virus-Ankara (MVA) priming and fowlpox-virus booster elicit a stronger CD8+ T-cell response in mice against an HIV-1 epitope than does a DNA/poxvirus prime-booster approach

Biotechnol Appl Biochem. 2004 Jun;39(Pt 3):313-8. doi: 10.1042/BA20030176.

Abstract

A prime-boost strategy combining FWPV (fowlpox virus) and the MVA (modified vaccinia virus Ankara), both expressing HIV-1 multi-V3 epitope polypeptides, was compared with a DNA-based Semliki Forest virus replicon/poxvirus approach for the induction of a CD8(+) T-cell response. Priming mice with recombinant MVA and boosting with recombinant FWPV, and not in the reverse order, increased the number of specific interferon-gamma-secreting cells in relation to the homologous combinations. Moreover, the improvement of the CD8(+) T-cell response with this combination was remarkably higher than that obtained by priming with a DNA vector containing a Semliki Forest virus replicon expressing the multi-epitope polypeptide and boosting either with recombinant MVA or FWPV. These results open a new and attractive alternative for vaccine preparation against HIV-1 using different immunogens.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • CD8-Positive T-Lymphocytes / immunology*
  • Cell Line, Tumor
  • Epitopes / genetics
  • Epitopes / immunology*
  • Female
  • Fowlpox virus / genetics
  • Fowlpox virus / immunology*
  • HIV-1 / genetics
  • HIV-1 / immunology*
  • Immunization, Secondary*
  • Interferon-gamma / metabolism
  • Mastocytoma / pathology
  • Mice
  • Mice, Inbred BALB C
  • Recombination, Genetic
  • Spleen / cytology
  • Vaccination
  • Vaccines, DNA*
  • Vaccinia virus / genetics
  • Vaccinia virus / immunology*

Substances

  • Epitopes
  • Vaccines, DNA
  • Interferon-gamma